TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06374277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Med AAAction intervention
Description: The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Med AAAction intervention
Description: The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.
Study: NCT05432947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P16-093
Description: Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.
Study: NCT04873102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol Pill
Description: Danazol is a synthetic steroid derived from ethisterone, It suppresses the pituitary-ovarian axis by inhibiting the pituitary output of gonadotropins. The pituitary-suppressive action of danazol is reversible. Danazol has been approved in treating endometriosis, fibrocystic breast disease, hereditary angioedema, thrombocytopenic purpura, and other conditions. It is metabolized and eliminated by renal and fecal pathways. The mean half-life of danazol in healthy males is 9.7 hours. After 6 months of 200 mg three times a day dosing in endometriosis patients, the half-life of danazol was reported as 23.7 hours.~Adverse reactions from danazol include androgen like effects (i.e. weight gain, acne, mild hirsutism, edema, hair loss, voice change) and menstrual disturbances. The use of danazol in pregnancy is contraindicated. Other side effects include elevations in liver-enzyme levels and lipid abnormalities.
Study: NCT06298695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Schema Therapy
Description: Schema therapy focuses on adapting maladaptive schemas (i.e., core representations of oneself, others or the world) and dysfunctional personality traits, while also incorporating exposure therapy. It consists of a maximum of 40 sessions within one year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment As Usual according to the Dutch Multidisciplinary Guidelines Anxiety Disorders and the Dutch Quality Standard for Anxiety Disorders. TAU often consists of a continuation of Cognitive Behavioral Therapy (CBT) and (different) medications, sometimes in a more treatment-intensive format. There are no restrictions to TAU, except that it may not be schema therapy. The actual content of TAU will be tracked.
Study: NCT06312111

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: recommendation to increase physical activity
Description: education on the benefits of physical activity in PAH from the first visit and doctor's recommendation to increase physical activity above 5,000 steps a day in inactive patients and above 5,000 steps per person in active patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: recommendation to increase physical activity
Description: education on the benefits of physical activity in PAH from the first visit and doctor's recommendation to increase physical activity above 5,000 steps a day in inactive patients and above 5,000 steps per person in active patients
Study: NCT05930145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double stentriever
Description: Double stentriever technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single stentriever
Description: Single stentriever technique
Study: NCT05030909

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: transdiagnostic group treatment
Description: The individual and group sessions will integrate core principles from Motivational interviewing (provide information, address barriers), Cognitive Behavioural Therapy (psychoeducation regarding emotions, enhancing emotional awareness, cognitive restructuring, behavioural experiments, relaxation) , Acceptance Commitment Therapy (mindfulness, grounding, emotional and body awareness, enhancing cognitive flexibility), and aspects of Islamic psychology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: transdiagnostic group treatment
Description: The individual and group sessions will integrate core principles from Motivational interviewing (provide information, address barriers), Cognitive Behavioural Therapy (psychoeducation regarding emotions, enhancing emotional awareness, cognitive restructuring, behavioural experiments, relaxation) , Acceptance Commitment Therapy (mindfulness, grounding, emotional and body awareness, enhancing cognitive flexibility), and aspects of Islamic psychology.
Study: NCT05161520

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification combined with IOL and CTR implantation
Description: Device: CTR (276001G； OPHTEC BV, Netherlands) Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL is implanted.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: phacoemulsification combined with IOL implantation
Description: Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag.
Study: NCT05366985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket shield technique with computer guided sectioning of the root
Description: A computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. An implant was then placed.~Preoperative and Postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. Linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified Area Of Interest (AOI) were measured
Study: NCT05319743

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: Expansion of Medicaid, 01/01/2014
Study: NCT06107270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure biofeedback
Description: uninﬂated pressure sensor will be kept below the neck suboccipital

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure biofeedback
Description: uninﬂated pressure sensor will be kept below the neck suboccipital

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic ultra sound
Description: continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic ultra sound
Description: continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic ultra sound
Description: continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infra red radiation
Description: (R 125, 250watt, Philips)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infra red radiation
Description: (R 125, 250watt, Philips)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infra red radiation
Description: (R 125, 250watt, Philips)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation
Description: sustained contraction followed by relaxation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation
Description: sustained contraction followed by relaxation
Study: NCT05153148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-034858
Description: NDI-034858 oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-034858
Description: NDI-034858 oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-034858
Description: NDI-034858 oral capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NDI-034858-matching oral placebo capsule
Study: NCT05267925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CuraLin
Description: CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs.~The CuraLin formulation contains the following ingredients (per 2 capsules):~* Mormordica charantia (fruit) - 300mg~* Gymnema sylvestre (leaf) - 80mg~* Trigonella foenum-Graecum (seed) - 100mg~* Curcuma longa (rhizome) - 100mg~* Phyllanthus embilica officinalis (fruit) - 100mg~* Swertia chiraytia (leaf) - 80mg~* Syzgium Cumini (seed) - 100mg~* Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg~* Cinnamoum verum/zeylanicum - 40 mg~* Hydroxypropyl methylcellulose~* Rice Flour
Study: NCT04938219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gloves filled with warm tap water
Description: The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands
Study: NCT06486649

Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal Large Language Model Diagnosis
Description: Diagnosis for heart failure with preserved ejection fraction (HFpEF) using the multimodal large language model MedGuide-72B.

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine diagnostic and therapeutic procedure
Description: Routine diagnostic and therapeutic procedure
Study: NCT05408923

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Control group will get normal saline for irrigation throughout the case.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (0.05% chlorhexidine gluconate (CHG) in sterile water)
Description: Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
Study: NCT05625919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus for Injection (Albumin Bound)
Description: Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
Study: NCT05970835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants assigned to control group will receive the usual care provided by clinicians and physiotherapists from the Complexo Termal de Caldelas. Participants will have an educational session conducted by one of the researchers, and a paper sheet will be distributed with exercises and a written explanation of how to perform those exercises and the number of sets and repetitions. data collection will be conducted in moments t2 and t3 by a phone call.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Experimental group evaluation: balance, functionality- 30 Second Sit To Stand Test, Modified Medical Research Council and functional status questionnaire, pain using VAS, cognitive variables-Montreal Cognitive Assessment and self-reported thermal water effects.After evaluation the App will display exercises related to data collected. Outcome measures will be collected at baseline, and 1 week, 1 month and 3 months after baseline.~After evaluation the App will display exercises related to data collected concerning participants condition improvement.
Study: NCT05222425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xagrotin
Description: A herbal compound
Study: NCT04669964

Intervention type: PROCEDURE
Intervention: Intravenous Hydration
Description: Patients will receive daily intravenous hydration of normal saline based on their ileostomy output.
Study: NCT06003907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional
Description: hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional and complementary medicine methods
Description: The Graston Technique is a form of manual therapy known as instrument assisted soft tissue mobilization. Graston massage is performed using titanium-coated metal rods specially designed for different parts of the body.~Cupping therapy is a treatment method that creates a regional vacuum to increase the blood circulation of the person and provide healing.
Study: NCT06234696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: entrepreneurial intervention
Description: The experimental group will be given psychoeducation for 4 weeks.
Study: NCT06618703

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blood sample, urine sample, osteodensitometry
Description: Blood sample, urine sample, osteodensitometry
Study: NCT06618586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TodaysBaby
Description: The TodaysBaby intervention is comprised of: 1) Text message-delivered, short educational videos in the first 2 months after birth, with each video timed to match content addressing anticipated barriers and facilitators to adhering to guidelines (e.g. parental concerns that infant will choke while supine). Participants will also have access to a web portal where intervention videos will be maintained. 2) Text queries regarding safe sleep practices, which collect data on sleep practices in near real-time and provide reinforcement of adherence. Mothers will receive 1-2 text message questions weekly that assess sleep practices in near real-time .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TodaysBaby
Description: The TodaysBaby intervention is comprised of: 1) Text message-delivered, short educational videos in the first 2 months after birth, with each video timed to match content addressing anticipated barriers and facilitators to adhering to guidelines (e.g. parental concerns that infant will choke while supine). Participants will also have access to a web portal where intervention videos will be maintained. 2) Text queries regarding safe sleep practices, which collect data on sleep practices in near real-time and provide reinforcement of adherence. Mothers will receive 1-2 text message questions weekly that assess sleep practices in near real-time .
Study: NCT04982068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV low adjuvant dose
Description: standard dose of 202-CoV with low dose CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV low adjuvant dose
Description: standard dose of 202-CoV with low dose CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV low antigen dose
Description: low dose 202-CoV with CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV low antigen dose
Description: low dose 202-CoV with CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV standard dose
Description: standard dose 202-CoV with CpG / alum adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 202-CoV standard dose
Description: standard dose 202-CoV with CpG / alum adjuvant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study: NCT06459570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based exercises
Description: one experimental group with Virtual reality-based exercises. Subjects in the VR-based exercises will receive 12 sessions of the VR-based exercises treatment, administered four times a week over 3 weeks, with each session lasting approximately 60 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: standard physical therapy
Description: Second control group with standard physical therapy and occupational therapy treatment.Subjects in the control group will receive 12 sessions of physical therapy treatment involving passive and active range of motion exercises, muscle strengthening, and therapeutic stretching, administered four times a week over a span of 3 weeks, with each session lasting approximately 60 minutes.
Study: NCT05685862

Intervention type: DEVICE
Intervention: Laser Speckle Contrast Imaging using the PerfusiX-Imaging device
Description: Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
Study: NCT04988477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic care management
Description: Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 3 months.
Study: NCT04425473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equivalent amount of normal saline will be administrated intravenously suturing incision.
Study: NCT05366309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored education
Description: Tailored Education: A delegated investigator will review the SD memory card data and share the results with the participant and/or parent/guardian. The investigator will explain whether there are partial or critical errors to inhalation technique that have been recorded. The participant will be informed about their overall adherence; including how and when they used their asthma medications. If errors in medication use are identified, specific coaching will be provided to help eliminate errors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care education
Description: Participants randomised to this group will receive usual care in terms of their education.
Study: NCT05448287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and family planning
Description: Promotion of health and family planning behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Promotion of maternal, infant, and young child feeding behaviors and nutrition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Agriculture and homestead food production
Description: Promotion of knowledge and practices about homestead food production

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water, sanitation, and hygiene
Description: Promotion of behaviors to improve water, sanitation, and hygiene
Study: NCT06137287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BOTOX
Description: Intramuscular Injection
Study: NCT05222425

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Green tea
Description: Normal green tea
Study: NCT05317546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.
Study: NCT05389527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab+Lenvatinib
Description: After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight \<60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year.
Study: NCT06144268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZyMōt Multi (850µL)
Description: An amount of 850 µl untreated semen sample will be loaded into the inlet chamber with a help of a sterile insulin-type syringe. A volume of 750 µl of Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution medium will be placed on top of the membrane (outlet chamber). After 30 min of incubation in a humidified incubator (37°C), 500 µl of medium, containing the selected spermatozoa, will be retrieved from the upper side of the membrane (retrieval chamber). An amount of 400 µl will be necessary for the IUI procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Density Gradient Centrifugation
Description: The gradient columns will be prepared by placing 1 ml 80% gradient media in a centrifuge tube and an additional 1 ml of 40% gradient layered on top.~The raw semen sample will be placed on top of the gradient (1ml semen/gradient tube) and centrifuged at 300xg for 20 minutes. The sperm pellet will be collected and washed 2 times for 5 min at 800xg in Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution.~The resulted pellet will be resuspended in the washing solution in a volume that will provide at least 1x106 forward motile spermatozoa in 400 µl, as this amount is necessary for IUI procedure.
Study: NCT05183737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microcapsules with turmeric and propolis
Description: Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcapsules with turmeric and propolis
Description: Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks